hydroxyzine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
diphenylmethyl piperazine derivatives	1400	68-88-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: hydroxyzine pamoate hydroxizine hydroxyzin hydroxyzyne tranquizine hydroxyzine hydroxyzine hydrochloride hydroxyzine dihydrochloride hydroxyzine HCl	A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative. Molecular weight: 374.91 Formula: C21H27ClN2O2 CLOGP: 4 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 35.94 ALOGS: -3.61 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

hydroxyzine pamoate
hydroxizine
hydroxyzin
hydroxyzyne
tranquizine
hydroxyzine
hydroxyzine hydrochloride
hydroxyzine dihydrochloride
hydroxyzine HCl

A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.

Molecular weight: 374.91
Formula: C21H27ClN2O2
CLOGP: 4
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 35.94
ALOGS: -3.61
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
75	mg	O
75	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	700 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	15.24 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	80 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
April 12, 1956	FDA	PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	819.29	10.13	880	57649	131009	50415586
Intentional overdose	335.42	10.13	387	58142	62117	50484478
Intentional self-injury	294.26	10.13	231	58298	22881	50523714
Toxicity to various agents	288.70	10.13	708	57821	211791	50334804
Urticaria	211.14	10.13	464	58065	129097	50417498
Pruritus	206.59	10.13	758	57771	282810	50263785
Drug abuse	199.42	10.13	293	58236	59553	50487042
Cardio-respiratory arrest	134.18	10.13	231	58298	53661	50492934
Poisoning	128.30	10.13	110	58419	12319	50534276
Respiratory arrest	127.09	10.13	165	58364	29844	50516751
Pemphigus	124.63	10.13	3	58526	120163	50426432
Contraindicated product administered	120.88	10.13	15	58514	148943	50397652
Treatment failure	113.81	10.13	13	58516	137624	50408971
Synovitis	112.34	10.13	8	58521	123857	50422738
Joint swelling	111.98	10.13	73	58456	245213	50301382
Rheumatoid arthritis	105.80	10.13	51	58478	202499	50344096
Systemic lupus erythematosus	105.20	10.13	18	58511	140604	50405991
Poisoning deliberate	104.82	10.13	81	58448	7831	50538764
Glossodynia	100.52	10.13	9	58520	115560	50431035
Drug dependence	95.37	10.13	116	58413	19643	50526952
Anxiety	90.56	10.13	426	58103	177180	50369415
Cardiac arrest	90.07	10.13	256	58273	83395	50463200
Suicide attempt	89.52	10.13	190	58339	51542	50495053
Drug intolerance	83.77	10.13	78	58451	219026	50327569
Dermatitis atopic	81.14	10.13	51	58478	3535	50543060
Anticholinergic syndrome	80.43	10.13	40	58489	1755	50544840
Arthropathy	76.17	10.13	44	58485	157862	50388733
Burning mouth syndrome	66.05	10.13	23	58506	400	50546195
Somnolence	65.05	10.13	352	58177	154633	50391962
Suicidal ideation	65.04	10.13	175	58354	55210	50491385
Therapeutic product effect decreased	64.07	10.13	39	58490	136011	50410584
Abdominal discomfort	62.93	10.13	107	58422	231534	50315061
Electrocardiogram QT prolonged	61.99	10.13	165	58364	51721	50494874
Wound	61	10.13	23	58506	105771	50440824
Skin plaque	59.27	10.13	53	58476	6275	50540320
Irritability	56.99	10.13	111	58418	28315	50518280
Drug reaction with eosinophilia and systemic symptoms	55.78	10.13	110	58419	28314	50518281
Hepatic enzyme increased	54.75	10.13	47	58482	137333	50409262
Psoriasis	53.86	10.13	189	58340	68811	50477784
Eczema	53.46	10.13	95	58434	22607	50523988
Infusion related reaction	52.10	10.13	72	58457	169485	50377110
Chronic spontaneous urticaria	50.54	10.13	20	58509	504	50546091
Angioedema	50.36	10.13	125	58404	37551	50509044
Urticaria thermal	49.79	10.13	15	58514	160	50546435
Maternal exposure during pregnancy	46.96	10.13	70	58459	159708	50386887
Prescription form tampering	45.59	10.13	19	58510	549	50546046
Scratch	45.37	10.13	41	58488	4921	50541674
Chemical submission	44.38	10.13	14	58515	176	50546419
Overdose	44.20	10.13	230	58299	99497	50447098
Victim of chemical submission	43.78	10.13	15	58514	248	50546347
Helicobacter infection	42.85	10.13	4	58525	49698	50496897
Alopecia	42.08	10.13	144	58385	244903	50301692
Bradypnoea	39.69	10.13	31	58498	3043	50543552
Drug ineffective	39.61	10.13	689	57840	818644	49727951
Lower respiratory tract infection	38.62	10.13	32	58497	95169	50451426
Suspected suicide	37.13	10.13	38	58491	5319	50541276
Depression	37.10	10.13	322	58207	165101	50381494
Asphyxia	36.71	10.13	38	58491	5389	50541206
Alcoholism	36.55	10.13	23	58506	1597	50544998
Rash maculo-papular	35.19	10.13	88	58441	26553	50520042
Drug screen positive	34.88	10.13	30	58499	3372	50543223
Intentional product misuse	34.74	10.13	126	58403	46608	50499987
Mastocytosis	33.88	10.13	15	58514	504	50546091
Hallucination, gustatory	33.11	10.13	9	58520	64	50546531
Urinary retention	33.02	10.13	85	58444	26105	50520490
Multiple drug therapy	32.81	10.13	23	58506	1914	50544681
Mixed liver injury	32.51	10.13	29	58500	3422	50543173
Long QT syndrome	32.13	10.13	27	58502	2940	50543655
Drug hypersensitivity	31.00	10.13	434	58095	250576	50296019
Allergy test positive	30.67	10.13	13	58516	392	50546203
Faecal vomiting	29.28	10.13	14	58515	563	50546032
Serotonin syndrome	28.91	10.13	78	58451	24635	50521960
Infection	28.75	10.13	103	58426	172851	50373744
Musculoskeletal stiffness	26.72	10.13	69	58460	128412	50418183
Metabolic acidosis	26.62	10.13	102	58427	38723	50507872
Insomnia	26.48	10.13	314	58215	174551	50372044
Agitation	26.37	10.13	127	58402	53257	50493338
Parkinsonism	26.15	10.13	41	58488	8806	50537789
Perfume sensitivity	25.63	10.13	13	58516	595	50546000
Miosis	25.62	10.13	34	58495	6276	50540319
Folliculitis	25.30	10.13	7	58522	39218	50507377
Impaired healing	25.29	10.13	26	58503	69760	50476835
Withdrawal syndrome	24.18	10.13	59	58470	17531	50529064
General physical health deterioration	23.55	10.13	85	58444	142349	50404246
Muscle injury	23.24	10.13	7	58522	37104	50509491
Disturbance in attention	23.10	10.13	84	58445	31102	50515493
Diet failure	22.67	10.13	6	58523	38	50546557
Labile hypertension	22.60	10.13	11	58518	460	50546135
Coma	22.36	10.13	127	58402	56752	50489843
Psychotic symptom	21.96	10.13	15	58514	1197	50545398
Altered state of consciousness	21.58	10.13	65	58464	21845	50524750
Panic attack	21.58	10.13	60	58469	19282	50527313
Dermatitis exfoliative generalised	21.35	10.13	22	58507	3104	50543491
Neutropenia	20.87	10.13	94	58435	147871	50398724
Blood immunoglobulin E increased	20.61	10.13	19	58510	2340	50544255
Nodular rash	20.39	10.13	8	58521	197	50546398
Product dose omission issue	20.35	10.13	312	58217	183526	50363069
Interstitial lung disease	20.20	10.13	19	58510	53157	50493438
Lymphomatoid papulosis	20.20	10.13	7	58522	120	50546475
Joint ankylosis	20.19	10.13	12	58517	752	50545843
Hereditary angioedema	20.09	10.13	28	58501	5414	50541181
Pancreatitis	20.06	10.13	100	58429	42514	50504081
Sleep disorder	20.01	10.13	124	58405	57159	50489436
Plasma cell myeloma	19.45	10.13	6	58523	31316	50515279
Distributive shock	19.14	10.13	12	58517	828	50545767
Off label use	19.11	10.13	411	58118	474015	50072580
Decreased eye contact	19.10	10.13	8	58521	234	50546361
Migraine	18.69	10.13	150	58379	75130	50471465
Photosensitivity reaction	18.49	10.13	44	58485	12867	50533728
Depressed level of consciousness	18.48	10.13	113	58416	51840	50494755
Arthralgia	18.26	10.13	378	58151	438324	50108271
Binge eating	18.24	10.13	9	58520	388	50546207
Cold agglutinins positive	18.10	10.13	5	58524	38	50546557
Sensitivity to weather change	18.00	10.13	28	58501	5973	50540622
Toxic skin eruption	17.94	10.13	40	58489	11211	50535384
Red blood cell sedimentation rate increased	17.62	10.13	6	58523	29410	50517185
Akathisia	17.55	10.13	33	58496	8196	50538399
Aggression	17.47	10.13	59	58470	21057	50525538
Skin lesion	17.33	10.13	69	58460	26658	50519937
Burnout syndrome	17.20	10.13	7	58522	190	50546405
Anaemia	17.15	10.13	198	58331	252258	50294337
Feeling abnormal	17.11	10.13	221	58308	125271	50421324
Papule	17.01	10.13	23	58506	4322	50542273
Hyperleukocytosis	16.91	10.13	9	58520	455	50546140
Pneumonia	16.65	10.13	323	58206	378078	50168517
Derailment	16.62	10.13	5	58524	53	50546542
Dementia	16.27	10.13	48	58481	15949	50530646
Emotional distress	16.24	10.13	71	58458	28592	50518003
Wound secretion	16.17	10.13	21	58508	3796	50542799
Lip erythema	16.09	10.13	6	58523	128	50546467
Wrong technique in device usage process	16.09	10.13	17	58512	2469	50544126
Mast cell activation syndrome	15.92	10.13	8	58521	359	50546236
Temperature intolerance	15.79	10.13	30	58499	7509	50539086
Irritable bowel syndrome	15.62	10.13	22	58507	51419	50495176
Hip arthroplasty	15.35	10.13	8	58521	30421	50516174
Blood cholesterol decreased	15.01	10.13	10	58519	766	50545829
Mydriasis	14.98	10.13	36	58493	10591	50536004
Injection site mass	14.96	10.13	46	58483	15634	50530961
Drug withdrawal syndrome	14.88	10.13	63	58466	25018	50521577
Linear IgA disease	14.81	10.13	12	58517	1242	50545353
Discomfort	14.59	10.13	70	58459	108310	50438285
Gastrointestinal disorder	14.55	10.13	58	58471	94398	50452197
Stomatitis	14.51	10.13	64	58465	101280	50445315
Superior mesenteric artery syndrome	14.41	10.13	5	58524	86	50546509
Affect lability	14.36	10.13	32	58497	8966	50537629
Apallic syndrome	14.31	10.13	9	58520	624	50545971
Post-traumatic stress disorder	14.21	10.13	21	58508	4282	50542313
Asthma	14.21	10.13	162	58367	89175	50457420
Initial insomnia	14.15	10.13	23	58506	5092	50541503
Tonsillar hypertrophy	14.01	10.13	10	58519	856	50545739
Accidental overdose	13.95	10.13	52	58477	19481	50527114
Postural orthostatic tachycardia syndrome	13.95	10.13	10	58519	862	50545733
Dermatitis	13.77	10.13	42	58487	14209	50532386
Cholestasis	13.69	10.13	62	58467	25339	50521256
Exposure during pregnancy	13.62	10.13	83	58446	120932	50425663
C-reactive protein increased	13.58	10.13	36	58493	66438	50480157
Talipes	13.55	10.13	12	58517	1402	50545193
Urticaria chronic	13.46	10.13	8	58521	501	50546094
Skin discolouration	13.44	10.13	74	58455	32683	50513912
Superior sagittal sinus thrombosis	13.41	10.13	9	58520	698	50545897
Knee arthroplasty	13.39	10.13	13	58516	35833	50510762
Illness	13.31	10.13	60	58469	24480	50522115
Alpha 1 globulin increased	13.27	10.13	5	58524	110	50546485
Restless arm syndrome	13.25	10.13	4	58525	43	50546552
Transverse sinus thrombosis	13.25	10.13	8	58521	516	50546079
Pleural effusion	13.20	10.13	49	58480	81405	50465190
Fatigue	13.16	10.13	677	57852	706924	49839671
Ehlers-Danlos syndrome	13.02	10.13	5	58524	116	50546479
Hallucination, olfactory	13.01	10.13	6	58523	222	50546373
Granulomatous liver disease	13.00	10.13	9	58520	734	50545861
Eyelid haemangioma	12.90	10.13	3	58526	10	50546585
Hypercreatininaemia	12.80	10.13	7	58522	374	50546221
Exposure via ingestion	12.79	10.13	16	58513	2787	50543808
Micrognathia	12.70	10.13	6	58523	235	50546360
Hallucination, visual	12.56	10.13	45	58484	16537	50530058
Social anxiety disorder	12.46	10.13	7	58522	394	50546201
Dependence	12.45	10.13	13	58516	1862	50544733
Pain of skin	12.39	10.13	28	58501	7919	50538676
Malignant neoplasm progression	12.38	10.13	39	58490	68085	50478510
Breast adenoma	12.35	10.13	4	58525	55	50546540
Swelling	12.33	10.13	161	58368	200711	50345884
Retrograde amnesia	12.30	10.13	7	58522	404	50546191
Multiple fractures	12.27	10.13	25	58504	6586	50540009
Alpha 2 globulin increased	12.24	10.13	5	58524	137	50546458
Fat necrosis	12.19	10.13	8	58521	597	50545998
Respiratory depression	12.18	10.13	36	58493	11974	50534621
Erythema	12.05	10.13	237	58292	146177	50400418
Substance abuse	12.03	10.13	19	58510	4105	50542490
Iron deficiency	11.88	10.13	23	58506	5839	50540756
Pneumonitis	11.86	10.13	10	58519	29500	50517095
Negative thoughts	11.76	10.13	9	58520	857	50545738
Bruxism	11.76	10.13	16	58513	3024	50543571
Nightmare	11.63	10.13	43	58486	16043	50530552
Herpes zoster meningoencephalitis	11.56	10.13	6	58523	288	50546307
Pulmonary fibrosis	11.50	10.13	7	58522	24430	50522165
Bronchial wall thickening	11.41	10.13	9	58520	896	50545699
Drug interaction	11.41	10.13	307	58222	199314	50347281
Dystonia	11.39	10.13	35	58494	11891	50534704
Vascular stent thrombosis	11.38	10.13	9	58520	900	50545695
Atrial fibrillation	11.34	10.13	70	58459	101675	50444920
Gastrointestinal ischaemia	11.10	10.13	5	58524	175	50546420
Blood pressure decreased	11.07	10.13	106	58423	55803	50490792
Ventricular fibrillation	11.04	10.13	32	58497	10527	50536068
Occipital neuralgia	11.03	10.13	6	58523	317	50546278
Formication	10.92	10.13	17	58512	3629	50542966
Tremor	10.84	10.13	190	58339	114713	50431882
Osteonecrosis of jaw	10.81	10.13	13	58516	32513	50514082
Breath odour	10.80	10.13	10	58519	1238	50545357
Loss of personal independence in daily activities	10.79	10.13	43	58486	70007	50476588
Bipolar disorder	10.75	10.13	24	58505	6733	50539862
Product use in unapproved indication	10.74	10.13	191	58338	115628	50430967
Sinusitis	10.72	10.13	136	58393	170422	50376173
Acidosis	10.70	10.13	31	58498	10196	50536399
Febrile bone marrow aplasia	10.70	10.13	23	58506	6288	50540307
Gastrointestinal haemorrhage	10.68	10.13	46	58483	73275	50473320
Tardive dyskinesia	10.63	10.13	25	58504	7254	50539341
Neuropathy peripheral	10.56	10.13	67	58462	96690	50449905
Hypertriglyceridaemia	10.47	10.13	21	58508	5470	50541125
Mucosal inflammation	10.46	10.13	19	58510	40123	50506472
Hypertonic bladder	10.43	10.13	15	58514	2985	50543610
Eosinophilia	10.41	10.13	46	58483	18606	50527989
Crying	10.39	10.13	49	58480	20367	50526228
Activation syndrome	10.39	10.13	5	58524	204	50546391
Staphylococcal skin infection	10.37	10.13	8	58521	771	50545824
Thrombocytopenia	10.35	10.13	96	58433	127577	50419018
Oedema mouth	10.33	10.13	13	58516	2277	50544318
Peripheral circulatory failure	10.29	10.13	7	58522	555	50546040
Therapeutic product effect incomplete	10.17	10.13	63	58466	91452	50455143
Stress	10.16	10.13	101	58428	53692	50492903

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	567	10.92	560	28353	89686	29455928
Toxicity to various agents	317.79	10.92	590	28323	173071	29372543
Drug abuse	142.42	10.92	269	28644	79614	29466000
Intentional overdose	95.17	10.92	150	28763	38378	29507236
Respiratory arrest	89.32	10.92	118	28795	25715	29519899
Pruritus	80.39	10.92	274	28639	116575	29429039
Poisoning	73.77	10.92	68	28845	9925	29535689
Cardio-respiratory arrest	67.15	10.92	151	28762	50450	29495164
Coma	66.68	10.92	130	28783	39320	29506294
Dermatitis atopic	59.01	10.92	33	28880	2186	29543428
Suicidal behaviour	58.57	10.92	28	28885	1337	29544277
Overdose	55.55	10.92	188	28725	79631	29465983
Ventricular tachyarrhythmia	52.43	10.92	17	28896	281	29545333
Urticaria	50.35	10.92	142	28771	54518	29491096
Parasomnia	48.86	10.92	17	28896	352	29545262
Drug reaction with eosinophilia and systemic symptoms	48.21	10.92	93	28820	27899	29517715
Cardiac arrest	48.05	10.92	188	28725	85403	29460211
Bradypnoea	44.09	10.92	28	28885	2343	29543271
Hyperthermia	43.79	10.92	50	28863	9380	29536234
Ureteric compression	43.04	10.92	13	28900	168	29545446
Suspected suicide	36.97	10.92	31	28882	3989	29541625
Priapism	35.98	10.92	32	28881	4456	29541158
Intentional self-injury	35.68	10.92	52	28861	12409	29533205
Chemical submission	35.02	10.92	8	28905	30	29545584
Toxic epidermal necrolysis	34.60	10.92	63	28850	18090	29527524
Electrocardiogram QT prolonged	34.36	10.92	95	28818	36042	29509572
Alcoholism	34.18	10.92	25	28888	2636	29542978
Exposure via ingestion	30.65	10.92	21	28892	1997	29543617
Personal relationship issue	29.87	10.92	11	28902	270	29545344
General physical health deterioration	29.77	10.92	34	28879	102823	29442791
Somnolence	28.49	10.92	173	28740	93782	29451832
Psoriasis	27.99	10.92	82	28831	32145	29513469
Abnormal sleep-related event	27.96	10.92	12	28901	444	29545170
Face oedema	26.70	10.92	41	28872	10242	29535372
Clonus	25.37	10.92	20	28893	2358	29543256
Haematoma muscle	24.82	10.92	14	28899	943	29544671
Sensory integrative dysfunction	24.70	10.92	6	28907	31	29545583
Non-cardiogenic pulmonary oedema	24.31	10.92	12	28901	615	29544999
Postmortem blood drug level	24.30	10.92	8	28905	139	29545475
Emotional disorder of childhood	24.24	10.92	6	28907	34	29545580
Dermatitis exfoliative generalised	23.79	10.92	21	28892	2895	29542719
Autism spectrum disorder	23.66	10.92	18	28895	2014	29543600
Anticholinergic syndrome	22.97	10.92	13	28900	881	29544733
Electrocardiogram QRS complex prolonged	22.92	10.92	24	28889	4086	29541528
Pyelocaliectasis	22.90	10.92	14	28899	1095	29544519
Drug dependence	22.82	10.92	58	28855	20923	29524691
Tachyphrenia	22.22	10.92	14	28899	1155	29544459
Febrile bone marrow aplasia	21.51	10.92	31	28882	7320	29538294
Myocardial infarction	21.04	10.92	48	28865	110248	29435366
Respiratory depression	20.95	10.92	43	28870	13480	29532134
Stereotypy	20.86	10.92	11	28902	648	29544966
Tachycardia	20.48	10.92	131	28782	72279	29473335
Rash	20.08	10.92	278	28635	189541	29356073
Disease progression	19.70	10.92	31	28882	81885	29463729
Mumps	19.62	10.92	6	28907	81	29545533
Miosis	19.50	10.92	31	28882	7978	29537636
Echolalia	19.36	10.92	8	28905	269	29545345
Drug ineffective	18.99	10.92	246	28667	362924	29182690
Mental disorder	18.79	10.92	40	28873	12865	29532749
Bladder dilatation	18.43	10.92	13	28900	1295	29544319
Dry skin	18.07	10.92	57	28856	23250	29522364
Agitation	17.84	10.92	98	28815	51206	29494408
Drug screen positive	17.38	10.92	20	28893	3781	29541833
Fixed eruption	17.06	10.92	12	28901	1190	29544424
Agoraphobia	16.95	10.92	7	28906	235	29545379
Intentional product misuse	16.94	10.92	73	28840	34588	29511026
Psychotic disorder	16.92	10.92	51	28862	20303	29525311
Suicidal ideation	16.88	10.92	73	28840	34643	29510971
Drug withdrawal syndrome	16.81	10.92	47	28866	17937	29527677
Injection site reaction	16.66	10.92	35	28878	11153	29534461
Infective pulmonary exacerbation of cystic fibrosis	16.38	10.92	25	28888	6211	29539403
Disturbance in attention	16.25	10.92	52	28861	21372	29524242
Eosinophilia	16.10	10.92	53	28860	22108	29523506
Tremor	16.08	10.92	125	28788	73413	29472201
Rash erythematous	16.05	10.92	52	28861	21510	29524104
Serotonin syndrome	15.62	10.92	45	28868	17467	29528147
Hypercapnic coma	15.58	10.92	6	28907	167	29545447
Generalised oedema	15.56	10.92	34	28879	11131	29534483
Administration related reaction	15.46	10.92	5	28908	82	29545532
Diarrhoea infectious	15.35	10.92	8	28905	460	29545154
Eczema	14.81	10.92	38	28875	13788	29531826
Neurodevelopmental disorder	14.67	10.92	7	28906	333	29545281
C-reactive protein increased	14.66	10.92	13	28900	44250	29501364
Neonatal respiratory distress	14.59	10.92	8	28905	510	29545104
Anaemia	14.58	10.92	126	28787	200825	29344789
Pneumonia	14.54	10.92	223	28690	319949	29225665
Thyroiditis acute	14.31	10.92	5	28908	105	29545509
Prothrombin time ratio decreased	14.30	10.92	7	28906	352	29545262
Acute generalised exanthematous pustulosis	14.13	10.92	22	28891	5561	29540053
Speech disorder developmental	14.11	10.92	13	28900	1894	29543720
Victim of crime	14.05	10.92	7	28906	366	29545248
Throat tightness	14.01	10.92	25	28888	7066	29538548
Rheumatoid arthritis	13.93	10.92	7	28906	32145	29513469
Meningioma	13.72	10.92	11	28902	1329	29544285
Sinus tachycardia	13.71	10.92	39	28874	15030	29530584
Faecal vomiting	13.62	10.92	7	28906	391	29545223
Victim of homicide	13.60	10.92	5	28908	122	29545492
Cerebrovascular accident	13.46	10.92	35	28878	76876	29468738
Diarrhoea	13.37	10.92	237	28676	332461	29213153
Pupillary reflex impaired	13.23	10.92	11	28902	1398	29544216
Mixed dementia	12.86	10.92	6	28907	271	29545343
Neurosis	12.86	10.92	5	28908	143	29545471
Acute respiratory distress syndrome	12.53	10.92	50	28863	22885	29522729
Arthritis allergic	12.43	10.92	3	28910	15	29545599
Suicide attempt	12.42	10.92	66	28847	34044	29511570
Cerebral disorder	12.02	10.92	13	28900	2295	29543319
Chronic spontaneous urticaria	12.02	10.92	4	28909	72	29545542
Anion gap	11.99	10.92	8	28905	728	29544886
Post-traumatic stress disorder	11.89	10.92	11	28902	1611	29544003
Atrial fibrillation	11.85	10.92	58	28855	105588	29440026
Cardiac failure congestive	11.82	10.92	37	28876	76544	29469070
Injection site mass	11.77	10.92	20	28893	5435	29540179
Aplastic anaemia	11.77	10.92	24	28889	7486	29538128
Anxiety	11.56	10.92	131	28782	85234	29460380
Pharyngeal dyskinesia	11.46	10.92	3	28910	22	29545592
Alcohol withdrawal syndrome	11.43	10.92	10	28903	1363	29544251
Aspirin-exacerbated respiratory disease	11.28	10.92	6	28907	360	29545254
Drug diversion	11.25	10.92	8	28905	807	29544807
Neuropathy peripheral	11.18	10.92	34	28879	70993	29474621

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	1318.52	10.20	1442	71999	222972	64202319
Toxicity to various agents	580.72	10.20	1277	72164	362236	64063055
Intentional overdose	307.53	10.20	442	72999	89502	64335789
Drug abuse	275.61	10.20	520	72921	131854	64293437
Urticaria	248.38	10.20	530	72911	146787	64278504
Pruritus	225.42	10.20	824	72617	311576	64113715
Respiratory arrest	205.85	10.20	277	73164	52708	64372583
Poisoning	205.01	10.20	182	73259	21697	64403594
Intentional self-injury	198.62	10.20	203	73238	28841	64396450
Cardio-respiratory arrest	185.73	10.20	371	73070	98022	64327269
Cardiac arrest	123.39	10.20	421	73020	153643	64271648
Dermatitis atopic	103.64	10.20	61	73380	3815	64421476
Anticholinergic syndrome	101.57	10.20	53	73388	2616	64422675
Suicide attempt	94.62	10.20	233	73208	70774	64354517
Drug reaction with eosinophilia and systemic symptoms	94.62	10.20	198	73243	54019	64371272
Poisoning deliberate	93.69	10.20	95	73346	13363	64411928
Somnolence	90.11	10.20	464	72977	203181	64222110
Synovitis	86.45	10.20	7	73434	99083	64326208
Joint swelling	83.99	10.20	73	73368	215309	64209982
Rheumatoid arthritis	82.48	10.20	42	73399	164252	64261039
Bradypnoea	78.42	10.20	57	73384	5102	64420189
Chemical submission	75.93	10.20	22	73419	206	64425085
Drug dependence	75.65	10.20	136	73305	33176	64392115
Overdose	73.66	10.20	368	73073	159198	64266093
Coma	70.58	10.20	240	73201	87375	64337916
Suspected suicide	65.62	10.20	64	73377	8590	64416701
Contraindicated product administered	64.77	10.20	21	73420	107808	64317483
Burning mouth syndrome	62.92	10.20	23	73418	471	64424820
Electrocardiogram QT prolonged	60.83	10.20	214	73227	79234	64346057
Eczema	60.79	10.20	116	73325	29604	64395687
Anxiety	60.16	10.20	416	73025	202233	64223058
Chronic spontaneous urticaria	55.21	10.20	21	73420	482	64424809
Skin plaque	54.87	10.20	59	73382	8881	64416410
Treatment failure	54.08	10.20	33	73408	116783	64308508
Pemphigus	53.75	10.20	4	73437	60697	64364594
Pericarditis	52.93	10.20	5	73436	62511	64362780
Drug intolerance	52.54	10.20	83	73358	187909	64237382
Arthropathy	50.87	10.20	38	73403	120929	64304362
Serotonin syndrome	50.31	10.20	127	73314	39155	64386136
Alcoholism	50.23	10.20	37	73404	3380	64421911
Urticaria thermal	49.60	10.20	15	73426	165	64425126
Suicidal behaviour	48.73	10.20	34	73407	2853	64422438
Intentional product misuse	48.01	10.20	186	73255	72109	64353182
Glossodynia	45.77	10.20	9	73432	64687	64360604
General physical health deterioration	44.29	10.20	105	73336	204320	64220971
Systemic lupus erythematosus	43.39	10.20	17	73424	77595	64347696
Asphyxia	41.76	10.20	53	73388	9513	64415778
Therapeutic product effect decreased	41.51	10.20	42	73399	115309	64309982
Parasomnia	41.48	10.20	17	73424	478	64424813
Ureteric compression	40.94	10.20	13	73428	170	64425121
Faecal vomiting	40.86	10.20	21	73420	1004	64424287
Disturbance in attention	40.83	10.20	121	73320	40953	64384338
Drug hypersensitivity	40.75	10.20	432	73009	237383	64187908
Psoriasis	40.13	10.20	175	73266	71528	64353763
Suicidal ideation	40.02	10.20	166	73275	66376	64358915
Dermatitis exfoliative generalised	39.79	10.20	41	73400	5875	64419416
Exposure via ingestion	38.57	10.20	37	73404	4865	64420426
Hyperthermia	38.56	10.20	66	73375	15484	64409807
Miosis	37.88	10.20	60	73381	13206	64412085
Lower respiratory tract infection	36.93	10.20	32	73409	94582	64330709
Anaemia	36.88	10.20	266	73175	378414	64046877
Victim of chemical submission	34.65	10.20	13	73428	287	64425004
Multiple drug therapy	34.48	10.20	25	73416	2229	64423062
Scratch	33.28	10.20	39	73402	6450	64418841
Hallucination, gustatory	33.13	10.20	9	73432	65	64425226
Hepatic enzyme increased	32.96	10.20	61	73380	129882	64295409
Agitation	32.74	10.20	192	73249	88175	64337116
Wound	32.18	10.20	24	73417	76453	64348838
Priapism	31.30	10.20	30	73411	3940	64421351
Angioedema	30.94	10.20	146	73295	61675	64363616
Pneumonia	30.55	10.20	451	72990	559125	63866166
Rash maculo-papular	30.41	10.20	120	73321	46906	64378385
Drug screen positive	30.33	10.20	35	73406	5694	64419597
Helicobacter infection	30.13	10.20	4	73437	38358	64386933
Pyelocaliectasis	30.07	10.20	16	73425	822	64424469
Drug withdrawal syndrome	29.98	10.20	91	73350	31200	64394091
Allergy test positive	29.95	10.20	13	73428	423	64424868
Irritability	29.87	10.20	101	73340	36645	64388646
Mastocytosis	29.61	10.20	13	73428	435	64424856
Respiratory depression	29.19	10.20	75	73366	23368	64401923
Insomnia	28.72	10.20	348	73093	197488	64227803
Infusion related reaction	28.54	10.20	94	73347	164373	64260918
Altered state of consciousness	28.06	10.20	101	73340	37801	64387490
Abdominal discomfort	27.17	10.20	111	73330	182211	64243080
Distributive shock	26.88	10.20	20	73421	1855	64423436
Long QT syndrome	26.54	10.20	31	73410	5108	64420183
Drug ineffective	26.20	10.20	743	72698	839504	63585787
Personal relationship issue	25.29	10.20	9	73432	170	64425121
Perfume sensitivity	24.83	10.20	13	73428	646	64424645
Depression	24.71	10.20	318	73123	182973	64242318
Psychotic symptom	24.56	10.20	20	73421	2118	64423173
Urinary retention	24.48	10.20	116	73325	49085	64376206
Maternal exposure during pregnancy	24.32	10.20	45	73396	95839	64329452
Eosinophilia	23.69	10.20	96	73345	37980	64387311
Dry skin	23.57	10.20	118	73323	51043	64374248
Injection site reaction	23.20	10.20	110	73331	46554	64378737
C-reactive protein increased	22.80	10.20	46	73395	94863	64330428
Diet failure	22.76	10.20	6	73435	38	64425253
Neuropathy peripheral	22.65	10.20	64	73377	117461	64307830
Tachyphrenia	22.50	10.20	18	73423	1858	64423433
Injection site mass	22.28	10.20	56	73385	17214	64408077
Arthritis allergic	21.98	10.20	5	73436	15	64425276
Febrile bone marrow aplasia	21.88	10.20	43	73398	11212	64414079
Mixed liver injury	21.79	10.20	29	73412	5452	64419839
Labile hypertension	21.46	10.20	11	73430	523	64424768
Atrial fibrillation	21.42	10.20	111	73330	170978	64254313
Accidental overdose	21.19	10.20	85	73356	33472	64391819
Infection	20.41	10.20	125	73316	184755	64240536
Fixed eruption	20.30	10.20	18	73423	2141	64423150
Musculoskeletal stiffness	20.29	10.20	72	73369	123134	64302157
Prothrombin time ratio decreased	20.23	10.20	12	73429	761	64424530
Binge eating	20.23	10.20	10	73431	440	64424851
Urticaria chronic	20.21	10.20	10	73431	441	64424850
Neutropenia	20.19	10.20	175	73266	239449	64185842
Panic attack	20.13	10.20	61	73380	20892	64404399
Sensitivity to weather change	20.05	10.20	31	73410	6683	64418608
Disease progression	20.03	10.20	88	73353	141592	64283699
Impaired healing	19.58	10.20	24	73417	60449	64364842
Tachycardia	19.52	10.20	258	73183	149321	64275970
Feeling abnormal	19.37	10.20	235	73206	133367	64291924
Drug resistance	19.11	10.20	8	73433	35094	64390197
Diarrhoea	19.09	10.20	653	72788	722051	63703240
Mydriasis	19.08	10.20	49	73392	15263	64410028
Haematoma muscle	18.99	10.20	16	73425	1777	64423514
Acute respiratory distress syndrome	18.79	10.20	91	73350	38844	64386447
Plasma cell myeloma	18.69	10.20	15	73426	46060	64379231
Withdrawal syndrome	18.59	10.20	64	73377	23428	64401863
Postmortem blood drug level	18.49	10.20	8	73433	258	64425033
Cerebral infarction	18.43	10.20	12	73429	41032	64384259
Renal impairment	18.40	10.20	85	73356	134932	64290359
Affect lability	18.27	10.20	35	73406	8955	64416336
Pleural effusion	18.26	10.20	78	73363	126481	64298810
Therapeutic product effect incomplete	18.04	10.20	59	73382	103423	64321868
Toxic epidermal necrolysis	18.03	10.20	87	73354	37079	64388212
Haemoglobin decreased	18.01	10.20	139	73302	194924	64230367
Malignant neoplasm progression	17.90	10.20	67	73374	112804	64312487
Victim of crime	17.75	10.20	9	73432	418	64424873
Joint ankylosis	17.71	10.20	11	73430	758	64424533
Pulmonary fibrosis	17.62	10.20	6	73435	29872	64395419
Electrocardiogram QRS complex prolonged	17.58	10.20	35	73406	9209	64416082
Thrombocytopenia	17.31	10.20	167	73274	223634	64201657
Red blood cell sedimentation rate increased	17.19	10.20	7	73434	31228	64394063
Abnormal sleep-related event	17.15	10.20	11	73430	802	64424489
Nodular rash	17.08	10.20	8	73433	312	64424979
Cold agglutinins positive	17.05	10.20	5	73436	49	64425242
Haemorrhage	16.97	10.20	41	73400	79310	64345981
Depressed level of consciousness	16.88	10.20	154	73287	81282	64344009
International normalised ratio increased	16.86	10.20	41	73400	79126	64346165
Exposure during pregnancy	16.72	10.20	40	73401	77635	64347656
Product dose omission issue	16.68	10.20	313	73128	194434	64230857
Non-cardiogenic pulmonary oedema	16.66	10.20	13	73428	1295	64423996
Photosensitivity reaction	16.62	10.20	52	73389	18121	64407170
Temperature intolerance	16.61	10.20	32	73409	8223	64417068
Post-traumatic stress disorder	16.34	10.20	22	73419	4183	64421108
Myocardial infarction	16.34	10.20	116	73325	165705	64259586
Alopecia	16.28	10.20	116	73325	165574	64259717
Aggression	16.19	10.20	99	73342	46133	64379158
Skin lesion	16.00	10.20	83	73358	36399	64388892
Poor feeding infant	15.80	10.20	6	73435	137	64425154
Hypercapnic coma	15.54	10.20	8	73433	384	64424907
Dyspnoea	15.52	10.20	665	72776	718009	63707282
Blood creatinine increased	15.40	10.20	91	73350	135691	64289600
Derailment	15.37	10.20	5	73436	71	64425220
Gastrointestinal haemorrhage	15.37	10.20	88	73353	132224	64293067
Haematoma	15.35	10.20	18	73423	46232	64379059
Hyperleukocytosis	15.30	10.20	15	73426	2025	64423266
Polymicrogyria	15.26	10.20	3	73438	3	64425288
Pancreatitis	15.15	10.20	118	73323	59489	64365802
Rash erythematous	15.09	10.20	101	73340	48532	64376759
Dementia	15.08	10.20	55	73386	20711	64404580
Cerebral disorder	15.07	10.20	22	73419	4507	64420784
Lip erythema	14.97	10.20	6	73435	159	64425132
Toxic skin eruption	14.80	10.20	52	73389	19232	64406059
Cerebral haemorrhage	14.79	10.20	22	73419	51068	64374223
Blood immunoglobulin E increased	14.77	10.20	20	73421	3824	64421467
Off label use	14.61	10.20	581	72860	632225	63793066
Muscle injury	14.43	10.20	6	73435	26431	64398860
Tremor	14.38	10.20	243	73198	147987	64277304
Face oedema	14.28	10.20	61	73380	24700	64400591
Alpha 1 globulin increased	14.28	10.20	5	73436	90	64425201
Wrong technique in device usage process	14.25	10.20	17	73424	2865	64422426
Pancytopenia	14.24	10.20	100	73341	143209	64282082
Clonus	14.07	10.20	25	73416	6042	64419249
Cardiac failure congestive	14.04	10.20	89	73352	130491	64294800
Substance abuse	14.00	10.20	32	73409	9260	64416031
Lymphomatoid papulosis	13.93	10.20	7	73434	319	64424972
Aplastic anaemia	13.82	10.20	41	73400	13879	64411412
Injection site induration	13.72	10.20	31	73410	8901	64416390
Peripheral circulatory failure	13.72	10.20	9	73432	682	64424609
Pupillary reflex impaired	13.37	10.20	17	73424	3056	64422235
Papule	13.25	10.20	25	73416	6325	64418966
Restless arm syndrome	13.23	10.20	4	73437	44	64425247
Tardive dyskinesia	13.16	10.20	31	73410	9147	64416144
Infective pulmonary exacerbation of cystic fibrosis	12.93	10.20	36	73405	11760	64413531
Mental disorder	12.90	10.20	62	73379	26383	64398908
Bladder dilatation	12.74	10.20	13	73428	1841	64423450
Administration related reaction	12.71	10.20	5	73436	126	64425165
Cerebrovascular accident	12.71	10.20	98	73343	137485	64287806
Acute myocardial infarction	12.68	10.20	39	73402	69679	64355612
Anion gap	12.67	10.20	13	73428	1854	64423437
Arthralgia	12.49	10.20	396	73045	441864	63983427
Breast adenoma	12.41	10.20	4	73437	55	64425236
Dyskinesia	12.34	10.20	82	73359	39306	64385985
Mental status changes	12.34	10.20	115	73326	61047	64364244
Initial insomnia	12.29	10.20	23	73418	5781	64419510
Autonomic nervous system imbalance	12.23	10.20	19	73422	4113	64421178
Sensation of blood flow	12.16	10.20	4	73437	59	64425232
Transverse sinus thrombosis	12.13	10.20	8	73433	612	64424679
Rash pruritic	12.12	10.20	109	73332	57295	64367996
Parkinsonism	12.12	10.20	40	73401	14333	64410958
Myelosuppression	12.08	10.20	6	73435	23824	64401467
Skin exfoliation	12.05	10.20	90	73351	44795	64380496
Hallucination, visual	11.98	10.20	63	73378	27771	64397520
Sensory integrative dysfunction	11.98	10.20	3	73438	15	64425276
Apallic syndrome	11.95	10.20	9	73432	850	64424441
Arthritis	11.87	10.20	52	73389	83762	64341529
Vaginal lesion	11.87	10.20	5	73436	151	64425140
Vasculitis	11.83	10.20	3	73438	18092	64407199
Alpha 2 globulin increased	11.74	10.20	5	73436	155	64425136
Hallucination, olfactory	11.74	10.20	7	73434	448	64424843
Mixed dementia	11.73	10.20	6	73435	284	64425007
Osteonecrosis of jaw	11.67	10.20	17	73424	39808	64385483
Steal syndrome	11.67	10.20	3	73438	17	64425274
Dermatitis	11.65	10.20	46	73395	17983	64407308
Multiple fractures	11.65	10.20	23	73418	6017	64419274
Administration site erythema	11.62	10.20	5	73436	159	64425132
Emotional disorder of childhood	11.52	10.20	3	73438	18	64425273
Superior mesenteric artery syndrome	11.48	10.20	5	73436	164	64425127
Wound secretion	11.42	10.20	21	73420	5211	64420080
Burnout syndrome	11.39	10.20	6	73435	302	64424989
Victim of homicide	11.26	10.20	5	73436	172	64425119
Retrograde amnesia	11.15	10.20	7	73434	492	64424799
Iron deficiency	11.13	10.20	25	73416	7152	64418139
Clostridium difficile infection	11.03	10.20	15	73426	36148	64389143
Erythema	11.03	10.20	285	73156	186785	64238506
Electric shock sensation	10.90	10.20	6	73435	330	64424961
Pharyngeal dyskinesia	10.89	10.20	3	73438	23	64425268
Leukopenia	10.88	10.20	69	73372	101173	64324118
White blood cell count decreased	10.88	10.20	121	73320	157716	64267575
Acute generalised exanthematous pustulosis	10.86	10.20	38	73403	14020	64411271
Adenoidectomy	10.85	10.20	4	73437	84	64425207
Thyroiditis acute	10.77	10.20	5	73436	191	64425100
Knee arthroplasty	10.69	10.20	9	73432	26990	64398301
Postural orthostatic tachycardia syndrome	10.69	10.20	7	73434	529	64424762
Emotional distress	10.68	10.20	74	73367	35964	64389327
Fatigue	10.66	10.20	722	72719	748008	63677283
Diabetic ketoacidosis	10.58	10.20	11	73430	29834	64395457
Tonsillar hypertrophy	10.58	10.20	10	73431	1291	64424000
Agoraphobia	10.56	10.20	7	73434	540	64424751
Cardiac failure	10.56	10.20	98	73343	132275	64293016
Dysuria	10.54	10.20	83	73358	41974	64383317
Mood altered	10.51	10.20	41	73400	15938	64409353
Sinusitis	10.40	10.20	111	73330	145817	64279474
Pain of skin	10.33	10.20	29	73412	9518	64415773
Interstitial lung disease	10.30	10.20	67	73374	97665	64327626
Liver function test abnormal	10.26	10.20	34	73407	59367	64365924

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Eyelid haemangioma	20.86	17.91	3	6	9	84660

Pharmacologic Action:

Source	Code	Description
ATC	N05BB01	NERVOUS SYSTEM PSYCHOLEPTICS ANXIOLYTICS Diphenylmethane derivatives
ATC	N05BB51	NERVOUS SYSTEM PSYCHOLEPTICS ANXIOLYTICS Diphenylmethane derivatives
FDA MoA	N0000000207	Histamine Receptor Antagonists
MeSH PA	D000982	Antipruritics
MeSH PA	D003879	Dermatologic Agents
MeSH PA	D018494	Histamine Agents
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006634	Histamine H1 Antagonists
MeSH PA	D018377	Neurotransmitter Agents
CHEBI has role	CHEBI:35474	anti-anxiety agents
CHEBI has role	CHEBI:37955	H1 receptor antagonists
CHEBI has role	CHEBI:50177	dermatologic agent
CHEBI has role	CHEBI:59683	antipruritic drugs
CHEBI has role	CHEBI:149553	anticoronaviral drug
FDA EPC	N0000175750	Antihistamine

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Dermatographic urticaria	indication	7632005	DOID:743
Atopic dermatitis	indication	24079001	DOID:3310
Allergic rhinitis	indication	61582004
Nasal discharge	indication	64531003
Urticaria	indication	126485001
Itching of skin	indication	418363000
Allergic conjunctivitis	indication	473460002	DOID:11204
Severe Pruritus	off-label use
Tachyarrhythmia	contraindication	6285003
Alcoholism	contraindication	7200002
Peptic ulcer	contraindication	13200003	DOID:750
Pulmonary edema	contraindication	19242006	DOID:11396
Myocardial infarction	contraindication	22298006	DOID:5844
Shock	contraindication	27942005
Hyperthyroidism	contraindication	34486009	DOID:7998
Acute hepatitis	contraindication	37871000
Hypertensive disorder	contraindication	38341003	DOID:10763
Hypothyroidism	contraindication	40930008	DOID:1459
Third trimester pregnancy	contraindication	41587001
Conduction disorder of the heart	contraindication	44808001
Chronic heart failure	contraindication	48447003
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Multiple organ failure	contraindication	57653000
Psychotic disorder	contraindication	69322001
Diabetes mellitus	contraindication	73211009	DOID:9351
Chronic idiopathic constipation	contraindication	82934008
Cor pulmonale	contraindication	83291003	DOID:8515
Open-angle glaucoma	contraindication	84494001	DOID:1067
Seizure disorder	contraindication	128613002
Cystic fibrosis	contraindication	190905008	DOID:1485
Angina pectoris	contraindication	194828000
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Sepsis syndrome	contraindication	238150007
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Continuous fever	contraindication	271751000
Smoking cessation assistance	contraindication	384742004
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Chronic myocardial ischemia	contraindication	413844008	DOID:3393
Disorder of coronary artery	contraindication	414024009
Myocardial ischemia	contraindication	414795007	DOID:3393
Smokes tobacco daily	contraindication	449868002
Severe Hypoxemia	contraindication
Theophylline Toxicity	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.53	Basic
pKa2	3.53	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	Ki	8.70	WOMBAT-PK	CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	6.42	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	7.30	CHEMBL
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		Ki	5.41	WOMBAT-PK
Envelope glycoprotein gp160	Viral envelope protein		Q75760_9HIV1		IC50	5.20	CHEMBL
Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120	Unclassified		Q6QLK5_9HIV1		IC50	5.20	CHEMBL

External reference:

ID	Source
4019782	VUID
N0000147873	NUI
D00672	KEGG_DRUG
4017874	VANDF
4017875	VANDF
4019782	VANDF
C0020404	UMLSCUI
CHEBI:5818	CHEBI
CHEMBL1201007	ChEMBL_ID
CHEMBL896	ChEMBL_ID
CHEMBL3186993	ChEMBL_ID
CHEMBL1200467	ChEMBL_ID
DB00557	DRUGBANK_ID
D006919	MESH_DESCRIPTOR_UI
3658	PUBCHEM_CID
7199	IUPHAR_LIGAND_ID
599	INN_ID
2192-20-3	SECONDARY_CAS_RN
30S50YM8OG	UNII
154987	RXNORM
4857	MMSL
4858	MMSL
4859	MMSL
6478	MMSL
7094	MMSL
d00907	MMSL
001451	NDDF
001452	NDDF
001453	NDDF
372856003	SNOMEDCT_US
80165005	SNOMEDCT_US
83933007	SNOMEDCT_US
83945003	SNOMEDCT_US
10246-75-0	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Vistaril	HUMAN PRESCRIPTION DRUG LABEL	1	0069-5410	CAPSULE	25 mg	ORAL	NDA	15 sections
Vistaril	HUMAN PRESCRIPTION DRUG LABEL	1	0069-5420	CAPSULE	50 mg	ORAL	NDA	15 sections
Vistaril	HUMAN PRESCRIPTION DRUG LABEL	1	0069-5440	SUSPENSION	25 mg	ORAL	NDA	15 sections
Hydroxyzine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5060	TABLET, FILM COATED	10 mg	ORAL	ANDA	13 sections
Hydroxyzine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5060	TABLET, FILM COATED	10 mg	ORAL	ANDA	13 sections
Hydroxyzine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5061	TABLET, FILM COATED	25 mg	ORAL	ANDA	13 sections
Hydroxyzine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5061	TABLET, FILM COATED	25 mg	ORAL	ANDA	13 sections
Hydroxyzine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5062	TABLET, FILM COATED	50 mg	ORAL	ANDA	13 sections
Hydroxyzine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5062	TABLET, FILM COATED	50 mg	ORAL	ANDA	13 sections
Hydroxyzine Pamoate	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1670	CAPSULE	25 mg	ORAL	ANDA	13 sections
Hydroxyzine Pamoate	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1671	CAPSULE	50 mg	ORAL	ANDA	13 sections
Hydroxyzine Pamoate	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1803	CAPSULE	25 mg	ORAL	ANDA	13 sections
Hydroxyzine Pamoate	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1804	CAPSULE	50 mg	ORAL	ANDA	13 sections
Hydroxyzine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0121-4822	SYRUP	10 mg	ORAL	ANDA	14 sections
Hydroxyzine Pamoate	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0613	CAPSULE	25 mg	ORAL	ANDA	14 sections
Hydroxyzine Pamoate	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0613	CAPSULE	25 mg	ORAL	ANDA	14 sections
hydroxyzine pamoate	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0615	CAPSULE	50 mg	ORAL	ANDA	14 sections
hydroxyzine pamoate	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0615	CAPSULE	50 mg	ORAL	ANDA	14 sections
hydroxyzine pamoate	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0674	CAPSULE	25 mg	ORAL	ANDA	14 sections
hydroxyzine pamoate	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0674	CAPSULE	25 mg	ORAL	ANDA	14 sections
Hydroxyzine pamoate	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0676	CAPSULE	50 mg	ORAL	ANDA	14 sections
Hydroxyzine pamoate	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0676	CAPSULE	50 mg	ORAL	ANDA	14 sections
Hydroxyzine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9877	INJECTION, SOLUTION	50 mg	INTRAMUSCULAR	ANDA	9 sections
Hydroxyzine	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9878	INJECTION, SOLUTION	50 mg	INTRAMUSCULAR	ANDA	9 sections
Hydroxyzine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0440-1617	TABLET, FILM COATED	25 mg	ORAL	ANDA	11 sections
Hydroxyzine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0517-4201	INJECTION, SOLUTION	25 mg	INTRAMUSCULAR	ANDA	11 sections
Hydroxyzine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0517-5601	INJECTION, SOLUTION	50 mg	INTRAMUSCULAR	ANDA	11 sections
Hydroxyzine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0517-5602	INJECTION, SOLUTION	50 mg	INTRAMUSCULAR	ANDA	11 sections
Hydroxyzine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0517-5610	INJECTION, SOLUTION	50 mg	INTRAMUSCULAR	ANDA	11 sections
Hydroxyzine Pamoate	HUMAN PRESCRIPTION DRUG LABEL	1	0555-0302	CAPSULE	50 mg	ORAL	ANDA	13 sections